TIDMNSCI
NetScientific PLC
16 December 2022
Reach: 16 December 2022
NetScientific plc
("NetScientific" or the "Company")
PDS Biotech Completes First Stage of Enrolment in Checkpoint
Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced
HPV16 Positive Head and Neck Cancer
VERSATILE-002 Phase 2 study investigates PDS0101 in combination
with Merck's KEYTRUDA(R) (pembrolizumab) in both checkpoint
inhibitor refractory and checkpoint inhibitor naïve patients
NetScientific Plc (AIM: NSCI), investment and commercialisation
group with an international portfolio of innovative life science,
sustainability and technology companies, reports that its portfolio
company, PDS Biotechnology Corporation (Nasdaq: PDSB), has
announced the completion of enrolment in the first stage of the
checkpoint inhibitor refractory group of its VERSATILE-002 Phase 2
study for the potential treatment of recurrent and/or metastatic
human papillomavirus (HPV16)-positive head and neck cancer. 90% of
HPV-associated head and neck cancers in the US are reported to be
caused by HPV16, as reported in a study published in the Journal of
Clinical Medicine.
VERSATILE-002 is a Phase 2, open-label, multicenter study of the
efficacy and safety of PDS0101 administered in combination with
pembrolizumab (KEYTRUDA(R) ) in adults with HPV16 and PD-L1
positive recurrent or metastatic head and neck squamous cell
carcinoma (HNSCC). VERSATILE-002 is investigating two patient
populations of HPV16-positive head and neck cancer patients whose
cancer has returned or spread. The first group has not been
previously treated with a checkpoint inhibitor (CPI naïve). The
second group of patients has failed treatments including checkpoint
inhibitor therapy (CPI refractory).
Dr Ilian Iliev, CEO of NetScientific, commented:
"We are delighted with PDS Biotech's continued progress in its
clinical trials, including the Phase 2 trial for combined therapy
with Merck's Keytruda(R) drug as detailed in their announcement.
Congratulations to Frank and his team with their company's
continued advancements ."
Dr Lauren V. Wood, Chief Medical Officer of PDS Biotech,
said:
"We are very pleased to have completed enrolment among
checkpoint inhibitor refractory patients in this first stage for
this group in our VERSATILE-002 Phase 2 study. This important
milestone follows continued positive progress with the Phase 2
study, including data presented at ASCO 2022 and updated at our
recent Head and Neck Cancer KOL Roundtable demonstrating the
potential of PDS0101 in combination with pembrolizumab as a
treatment for recurrent or metastatic HPV16-positive head and neck
cancer.
"Currently, there are no approved therapies for CPI refractory
head and neck cancer, with patients typically surviving less than a
year. Our intent with VERSATILE-002 is to investigate the potential
contribution that PDS0101 may have in improving the lives of
patients with advanced head and neck cancer."
A full version of PDS Biotech's announcement can be accessed
here .
-Ends-
For more information, please contact:
NetScientific
Ilian Iliev, CEO Via Belvedere Communications
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666
Belvedere Communications
John West / Llew Angus +44 (0) 203 008 6867
Email: nsci@belvederepr.com
About NetScientific
NetScientific plc (AIM: NSCI) is an investment and
commercialisation group with an international portfolio of
innovative life science, sustainability and technology
companies.
NetScientific identifies, invests in, and builds high growth
companies in the UK and internationally. The company adds value
through the proactive management of its portfolio, progressing to
key value inflection points, and delivering investment returns
through partial or full liquidity events.
NetScientific differentiates itself by employing a capital-light
investment approach, making judicial use of its balance sheet and
syndicating investments through its wholly owned VC subsidiary, EMV
Capital. The group secures a mixture of direct equity stakes and
carried interest stakes in its portfolio of companies, creating a
lean structure that can support a large portfolio.
NetScientific is headquartered in London, United Kingdom, and is
admitted to trading on AIM, a market operated by the London Stock
Exchange.
www.netscientific.net
About PDS Biotech
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing
a growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune(R) and
Infectimune(TM) T cell-activating technology platforms. We believe
our targeted Versamune(R) based candidates have the potential to
overcome the limitations of current immunotherapy by inducing large
quantities of high-quality, potent polyfunctional tumor specific
CD4+ helper and CD8+ killer T cells. To date, our lead Versamune(R)
clinical candidate, PDS0101, has demonstrated the potential to
reduce tumors and stabilize disease in combination with approved
and investigational therapeutics in patients with a broad range of
HPV-positive cancers in multiple Phase 2 clinical trials. Our
Infectimune(TM) based vaccines have also demonstrated the potential
to induce not only robust and durable neutralizing antibody
responses, but also powerful T cell responses, including
long-lasting memory T cell responses in pre-clinical studies to
date. To learn more, please visit www.pdsbiotech.com or follow us
on Twitter at @PDSBiotech.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUVVBRUUUUAAA
(END) Dow Jones Newswires
December 16, 2022 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2023 to Apr 2024
